Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

Sponsor
Novo Nordisk A/S
Study ID
NCT02060266
Phase
PHASE1
Status
Completed

Conditions

  • Diabetes
  • Healthy

Eligibility Criteria

Sex
MALE
Age
45 Years - 64 Years
Healthy Volunteers
Accepted

Interventions

  • semaglutide — DRUG
    Subjects will receive a single dose subcutaneously (s.c., under the skin).

Study Details

This trial is conducted in Europe. The aim of the trial is to investigate the absorption, metabolism and excretion after a single subcutaneous dose of \[3H\]-semaglutide in healthy male subjects.

Key Dates

First listed
Feb 12, 2014
Start date
Feb 4, 2014
Status verified
Mar 2017
Primary completion
Apr 28, 2014
Completion
Apr 28, 2014

Study Design

Enrollment
7 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide

Primary Outcome Measure

Concentration of the major metabolites of [3H]-semaglutide in plasma, urine, and faeces [ Time Frame: Up to 9 weeks following a single dose of 0.5 mg [3H]-semaglutide ]

Related Studies